Seems the NSCLC folks are starting from a tough position. Cant help thinking what would the responses be if the treatment was initiated at an earlier stage. That is when a person's immune system was more robust. Prior to the impact of cancer and drugs suppressive side effects on their immune response. It seems this is a challenge for any perspective new treatment. Kind of like attempting to resuscitate a patient when it's too late.
Ann: Encouraging Phase II TACTI-002 data reported at SITC 2020, page-11
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.0¢ | 33.0¢ | $1.220M | 3.642M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 57289 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 52306 | 3 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |